Irinotecan in small-cell lung cancer - Japanese trials

ONCOLOGY

Volumn 14, Issue 7 SUPPL. 5, 2000, Pages 57-62

  Fukuoka, Masahiro ^a   Masuda, Noriyuki ^b   Kudoh, Shinzo ^c   Negoro, Shunichi ^d  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c School of Medicine   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; ETOPOSIDE; IRINOTECAN; RADIOSENSITIZING AGENT;

CLINICAL TRIAL; HUMAN; JAPAN; LUNG TUMOR; REVIEW; SMALL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS; ETOPOSIDE; HUMANS; JAPAN; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 0034218539     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Seifter EJ, Ihde DC: Therapy of small-cell lung cancer: A perspective on two decades of clinical research. Semin Oncol 15:278-299, 1988.
2. Kunimoto T, Nitta K, Tanaka T, et al: Anti-tumor activity of 7-ethyl-10-[4-(1-poperidino)-1-poperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987.
3. Matsuzaki T, Yokokura T, Mutai M, et al:Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988.
4. Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 14:341-349, 1991.
5. Kawato Y, Aonuma M, Hirota Y, et al: Intra-cellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effet of CPT-11. Cancer Res 51:4187-4191, 1991.
6. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987.
7. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985.
8. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 10:241, 1991.
9. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
10. Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993.
11. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993.
12. Masuda N, Fukuoka M, Fujita A, et al: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 78:251-256, 1998.
13. Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068-1074, 1998.
14. Wang JC: DNA topoisomerases. Annu Rev Biochem 54:665-697, 1985.
15. Bertrand R, O'Connor PM, Kerrigan D, et al: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992.
16. Masuda N, Matsui K, Negoro S, et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16:3329-3334, 1998.
17. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12: 1833-1841, 1994.
18. Nakamura S, Kudoh S, Komuta K, et al: Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer (ED-SCLC): A study of the West Japan Lung Cancer Group (abstract). Proc Am Soc Clin Oncol 18:470a, 1999.